Form 4: Serina Therapeutics Director Gregory Bailey Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


Gregory Bailey, a director of Serina Therapeutics, reported the acquisition and disposal of 100 shares of common stock on May 20, 2024.

Summary

  • On May 20, 2024, Gregory Bailey, a director of Serina Therapeutics, engaged in transactions involving the company's common stock.
  • Bailey acquired 100 shares of common stock at a price of $9 per share.
  • Simultaneously, Bailey disposed of 100 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, reporting stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.

Key Dates

DateDescription
05/20/2024Date of stock transaction (acquisition and disposal)
05/22/2024Date of signature for the Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.